NBTY supplement sales set to top $3bn

Vitamin and nutritional supplement manufacturer NBTY has revealed in a financial guidance statement that it will post sales of over $3 billion for the year ending 30 September.

NBTY said that sales would hit $3.05 billion to $3.07 billion for the fiscal 2012. Consolidated EBITDA is expected to be between $556 million and $566 million while capital expenditure is estimated to reach $90-95 million.

Total debt to the end of September stood at $2.158 million. The firm will announce its full-year results by 30 November.

Meanwhile, NBTY has amended the credit agreement between its holding company Alphabet Holdings and Barclays Bank. The amendment will allow Alphabet to issue and sell contingent cash pay senior notes in a private placement to approximately $500 million.

The amount of debt on NBTY’s balance sheet increased significantly in 2011 when the firm was acquired by private equity firm Carlyle Group for $3.8 billion.